



FOR IMMEDIATE RELEASE

CONTACT: Israel Kreps
Laura Stace
ikreps@krepspr.com
lstace@krepspr.com
305.663.3543

COQUÍ RADIOPHARMACEUTICALS COMPLETES SCHEMATIC DESIGN OF \$330 MILLION MEDICAL ISOTOPE PRODUCTION FACILITY

Completed schematics marks another step towards becoming first U.S. commercial producer of Molybdenum-99

Miami, Fla. (April 7, 2015) – [Coquí RadioPharmaceuticals Corp.](#), a medical isotope company, today announces the completion of the schematic design of its \$330 million medical isotope production facility to be built in Alachua, Fla.

The finalization of Coquí Pharma's schematic design marks a significant milestone for the firm as they work toward becoming the first U.S. commercial supplier of the lifesaving radioisotope Molybdenum-99 (Mo-99), which is used in 20 million procedures each year in the U.S. Coquí Pharma will soon enter the detailed design phase as it readies to submit its construction license application to the Nuclear Regulatory Commission by the end of 2015.

Along with Argentinian nuclear engineering firm [INVAP](#), Coquí Pharma also contracted multi-disciplinary architectural, engineering and environmental firm [Gresham, Smith and Partners](#). Among the scope of work performed by Gresham, Smith and Partners is the design of the 250,000 square foot facility which is set to make a statement in supporting the global movement for environmentally sustainable design, construction and operational practice.

Architects ensured Coquí Pharma will operate on a minimum energy consumption rate with limited carbon dioxide emissions by mitigating solar exposure and enhancing the control of daylight throughout the building. Water efficiency also played a pivotal role in the design process, with the most effective use of water inside the facility as well as for the lush, tropical landscaping to be employed. The positioning of the structure on Coquí Pharma's 25 acres – gifted by the University of Florida Foundation – took into consideration two Heritage Oak trees that will essentially bookend the state-of-the-art facility.

"We have taken great care and the architects have created the design with the utmost precision to ensure Coquí Pharma leaves a minimal environmental footprint as we produce lifesaving medical isotopes," said

Carmen I. Bigles, President and CEO of Coquí Pharma. “Our goal was to incorporate the most innovative design while sustaining the environment, and Gresham, Smith and Partners have created a remarkable vision for Coquí Pharma.”

Medical isotopes are used in a variety of medical tests, including cancer screening. The most widely used medical isotope in the world is Technicium-99m (Tc-99m), which is derived from (Mo-99). Because of a very short lifespan, the isotope needs to be used in patients quickly after it is created. A major challenge for the industry is that the isotope is not produced in the U.S., and when a production facility in Canada is closed in 2018, there will be no producer from which to purchase Tc-99m in the Western Hemisphere. Existing international production sources tend to be older and often unreliable, potentially delaying life-saving diagnostics.

Coquí Pharma has contracted many leaders in their fields including [INVAP](#), [Gresham, Smith and Partners](#), nuclear engineering firm [MPR Associates](#) and international law firm [Hogan Lovells US, LLP](#).

About Coquí RadioPharmaceuticals Corp

Coquí RadioPharmaceuticals Corp. is a medical isotope company, dedicated to the production of Molybdenum-99, which is used in 20 million procedures each year in the U.S. The Puerto Rican company is based in Coral Gables, Fla., with the mission to bring the foremost medical isotope production facility in the Western Hemisphere to Alachua, Fla, and to create a commercially scalable, reliable supply of medical diagnostic and therapeutic radioisotopes in the U.S. For more information on Coquí RadioPharmaceuticals, visit www.coquipharma.com.